Gensight Biologics Debt 2025

Gensight Biologics Aktienanalyse

What does Gensight Biologics do?

Gensight Biologics SA is a biotechnology company specializing in the development of gene therapies for genetically inherited eye diseases. The company is based in Paris, France, with offices in Amsterdam and New York. The company's history began in 2012 when the founder, Bernard Gilly, had the idea to develop gene therapy for liver diseases. After several years of research and development, it became clear that the company could not develop a commercially viable solution due to the complexity of liver diseases and the high treatment costs. In 2013, the company shifted its focus to the development of gene therapies for genetically inherited eye diseases. Since then, Gensight Biologics SA has conducted several studies and clinical trials and is now a leading provider in this market segment. Gensight Biologics SA's business model is based on the development of gene therapies aimed at correcting the genetic defect and repairing the corresponding cells in the eye. The gene therapy is conducted using adeno-associated viruses (AAV), which introduce a normal gene into the diseased tissue. Gensight Biologics' particular focus is on the development of gene therapies for the treatment of eye diseases, with a focus on the research and treatment of rare diseases. The company has two central product lines. Firstly, it offers gene therapies targeting genetically inherited eye diseases such as retinitis pigmentosa (RP). This disease is inherited and leads to gradual loss of vision and, in severe cases, blindness. Gene therapy aims to repair the responsible gene and improve cell function and vision. Secondly, Gensight Biologics SA offers gene therapies targeting liver diseases such as Wilson's disease and gout, where copper and uric acid, respectively, are not properly metabolized. Here, gene therapy aims to repair the corresponding gene and reduce disease-related functional impairments. Gensight Biologics SA works closely with regulatory authorities and clinical partners to ensure the safety and efficacy of their gene therapies. The therapies are currently being tested in clinical trials to assess their effectiveness and safety. Gensight Biologics SA also collaborates with some of the world's leading doctors and researchers in the field of ophthalmology. While Gensight Biologics SA's gene therapies are still in the development phase, the clinical trials have shown promising results, and the company expects their therapies to be approved soon. The company follows a well-thought-out growth model and plans to develop further products for the treatment of eye diseases in the future. Overall, Gensight Biologics SA is a biotechnology company specialized in gene therapies, with a focus on researching and treating rare eye diseases. The company presents a promising investment option due to its innovative product range, close collaboration with researchers and clinical partners, and solid growth strategy. Gensight Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Gensight Biologics's Debt Structure

Gensight Biologics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Gensight Biologics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Gensight Biologics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Gensight Biologics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Gensight Biologics stock

What is the debt of Gensight Biologics this year?

Gensight Biologics has a debt level of 21.4 EUR this year.

What was the debt of Gensight Biologics compared to the previous year?

The debt of Gensight Biologics has increased by 195.15% compared to the previous year increased.

What are the consequences of high debt for investors in Gensight Biologics?

High debt can pose a risk for investors of Gensight Biologics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Gensight Biologics?

Low debt means that Gensight Biologics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Gensight Biologics affect the company?

An increase in debt of Gensight Biologics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Gensight Biologics affect the company?

A reduction in debt of Gensight Biologics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Gensight Biologics?

Some factors that can influence the debt of Gensight Biologics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Gensight Biologics so important for investors?

The debts of Gensight Biologics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Gensight Biologics take to change the debt?

To change the debt, Gensight Biologics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Gensight Biologics pay?

Over the past 12 months, Gensight Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gensight Biologics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Gensight Biologics?

The current dividend yield of Gensight Biologics is .

When does Gensight Biologics pay dividends?

Gensight Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gensight Biologics?

Gensight Biologics paid dividends every year for the past 0 years.

What is the dividend of Gensight Biologics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gensight Biologics located?

Gensight Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gensight Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gensight Biologics from 2/28/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 2/28/2025.

When did Gensight Biologics pay the last dividend?

The last dividend was paid out on 2/28/2025.

What was the dividend of Gensight Biologics in the year 2024?

In the year 2024, Gensight Biologics distributed 0 EUR as dividends.

In which currency does Gensight Biologics pay out the dividend?

The dividends of Gensight Biologics are distributed in EUR.